|1.||Russell, Stephen J: 3 articles (12/2013 - 06/2005)|
|2.||Peng, Kah-Whye: 2 articles (12/2013 - 06/2009)|
|3.||Ammayappan, Arun: 1 article (12/2013)|
|4.||Fu, Xinping: 1 article (11/2013)|
|5.||Tao, Lihua: 1 article (11/2013)|
|6.||Zhang, Xiaoliu: 1 article (11/2013)|
|7.||Rivera, Armando: 1 article (11/2013)|
|8.||Notni, Johannes: 1 article (01/2013)|
|9.||Pohle, Karolin: 1 article (01/2013)|
|10.||Wester, Hans-Jürgen: 1 article (01/2013)|
11/01/1999 - "However, in vivo studies have shown that echistatin, an RGD-containing disintegrin which binds to alpha(v)beta(3), inhibits bone resorption without changing the number of osteoclasts on the bone surface, suggesting inhibition of osteoclast activity. "
09/01/1994 - "Structure-activity studies of the s-echistatin inhibition of bone resorption."
03/01/1993 - "In this study echistatin, a naturally-occurring protein containing an RGD-sequence motif, was shown to completely inhibit osteoclast-mediated bone resorption in vivo. "
03/01/1998 - "These findings provide histological evidence for echistatin binding to osteoclasts and for inhibition of bone resorption in vivo, through reduced osteoclast efficacy, without apparent changes in osteoclast morphology."
03/01/1998 - "Echistatin, an RGD-containing peptide, was shown to inhibit the acute calcemic response to exogenous PTH or PTH-related protein (PTH-rP) in thyroparathyroidectomized rats, suggesting that echistatin inhibits bone resorption. "
01/01/2009 - "The data presented suggest that combined therapy with disintegrin - echistatin and alkyalting drug - mephalan may represent a new approach to more effective and safe cancer therapy."
11/15/2013 - "As echistatin has high binding affinity to αvβ3 integrin that is highly expressed on the surface of endothelial cells of tumor neovasculature, T cells engrafted with eCAR (T-eCAR) can efficiently lyse human umbilical vein endothelial cells and tumor cells that express αvβ3 integrin when tested in vitro. "
06/15/2005 - "Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression."
10/01/1997 - "These results demonstrate that echistatin is able to inhibit metastasis attachment and spreading in experimental system in vivo independently by its effect on the primary tumor."
01/01/1995 - "A major contribution of albolabrin, barbourin and echistatin appears to be by interference with other integrin receptors on the tumor cell surface. "
03/01/1993 - "Echistatin, a potential new drug for osteoporosis."
04/05/1996 - "Because echistatin also inhibits bone resorption, we measured the effects of adding another osteoporosis inhibitor, alendronate, in this system. "
03/01/1993 - "Echistatin or smaller derivative peptides may prove useful in the treatment of disorders characterized by excess bone resorption, such as osteoporosis and metastatic bone disease."
|4.||Bone Diseases (Bone Disease)
|5.||Melanoma (Melanoma, Malignant)
01/01/2013 - "We synthesized a series of five cyclo(RGDfK) peptide trimers and determined their α(v)β₃ integrin affinities in competition assays on α(v)β₃-expressing M21 human melanoma cells against ¹²⁵I-echistatin. "
01/01/1995 - "Echistatin inhibits the adhesion of murine melanoma cells to extracellular matrix components."
08/01/2000 - "The aim of this study was to establish the sequence of events downstream pp125FAK dephosphorylation that could be responsible for echistatin-induced disassembly of actin cytoskeleton and focal adhesions in fibronectin-adherent B16-BL6 melanoma cells. "
08/01/1997 - "B16-BL6 mouse melanoma cells cultured on fibronectin-coated dishes were detached by treatment with echistatin, an RGD-containing disintegrin. "
08/01/1997 - "Echistatin induces decrease of pp125FAK phosphorylation, disassembly of actin cytoskeleton and focal adhesions, and detachment of fibronectin-adherent melanoma cells."
|6.||Molecular Probes (Molecular Probe)
|9.||Snake Venoms (Snake Venom)
|10.||Proteins (Proteins, Gene)